DaVita Inc

DaVita’s upcoming Wolfe Research fireside chat will reveal how its tech‑driven, value‑based strategies and site expansion plans drive superior margins and future growth.

DaVita Inc., a leading provider of dialysis services, is expected to report a 5% revenue increase to $3.43 billion in its Q4 2025 earnings, driven by expanded patient volume, service diversification, and operational efficiency.

DaVita’s stock price has fluctuated following a ransomware attack that affected 2.7 million individuals, with the stock price dropping from a 52-week high of $179.60 to a recent close of $140.36.

DaVita’s stock price has fluctuated significantly over the past year, ranging from a 52-week high of $179.60 to a low of $126.07.

DaVita’s stock price has fluctuated significantly over the past year, reaching a 52-week high of $179.6 and a low of $126.07, with a current price of $134.39.

Barclays has revised its price target for DaVita to $160, a 24% increase from the current market price, indicating the investment bank believes the company’s stock is undervalued.

Davita’s stock price has experienced a mixed performance over the past year, with a moderate level of volatility and a current price of $140.37 USD.

DaVita’s 4.04% stock price surge is a modest gain, but a far cry from convincing investors of the company’s long-term prospects, and is likely a fleeting illusion rather than a sign of genuine recovery.

DaVita Inc has seen a significant 80% increase in its stock price over the past decade, driven by its commitment to delivering high-quality healthcare services and adapting to the evolving healthcare landscape.

DaVita Inc has experienced significant stock price growth over the past decade, with an 80% increase in value and a market value of approximately 11 billion USD.